These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33096223)

  • 41. Trials and tribulations: so many potential treatments, so few answers.
    Gazendam A; Nucci N; Ekhtiari S; Gohal C; Zhu M; Payne A; Bhandari M
    Int Orthop; 2020 Aug; 44(8):1467-1471. PubMed ID: 32447429
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
    Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
    Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019].
    Wang H; Jin XY; Pang B; Liu CX; Zheng WK; Yang FW; Pang WT; Zhang JH
    Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(6):1232-1241. PubMed ID: 32281330
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hydroxychloroquine and COVID-19: Lack of Efficacy and the Social Construction of Plausibility.
    Rughiniş C; Dima L; Vasile S
    Am J Ther; 2020; 27(6):e573-e583. PubMed ID: 33136577
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review.
    Cook JA; Hislop J; Adewuyi TE; Harrild K; Altman DG; Ramsay CR; Fraser C; Buckley B; Fayers P; Harvey I; Briggs AH; Norrie JD; Fergusson D; Ford I; Vale LD
    Health Technol Assess; 2014 May; 18(28):v-vi, 1-175. PubMed ID: 24806703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.
    Lewis K; Chaudhuri D; Alshamsi F; Carayannopoulos L; Dearness K; Chagla Z; Alhazzani W;
    PLoS One; 2021; 16(1):e0244778. PubMed ID: 33406138
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
    Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study).
    Namiki T; Takayama S; Arita R; Ishii T; Kainuma M; Makino T; Mimura M; Yoshino T; Nogami T; Arai M; Sato J; Tanaka K; Nakae H; Igari H; Ozawa Y; Shiko Y; Kawasaki Y; Nezu M; Ito T
    Trials; 2021 Jan; 22(1):23. PubMed ID: 33407828
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Meo SA; Klonoff DC; Akram J
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4539-4547. PubMed ID: 32373993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
    Shah S; Das S; Jain A; Misra DP; Negi VS
    Int J Rheum Dis; 2020 May; 23(5):613-619. PubMed ID: 32281213
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].
    Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M
    Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical trial research agenda on COVID-19 - the first two years in Germany and beyond.
    Hirt J; Janiaud P; Hemkens LG
    Z Evid Fortbild Qual Gesundhwes; 2022 Nov; 174():32-42. PubMed ID: 36180342
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.
    Hernandez AV; Roman YM; Pasupuleti V; Barboza JJ; White CM
    Ann Intern Med; 2020 Aug; 173(4):287-296. PubMed ID: 32459529
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drugs and convalescent plasma therapy for COVID-19: a survey of the interventional clinical studies in Italy after 1 year of pandemic.
    Puopolo M; Morciano C; Buoncervello M; De Nuccio C; Potenza RL; Toschi E; Palmisano L
    Trials; 2022 Jun; 23(1):527. PubMed ID: 35733167
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.